Valneva : ABPI Presentation on VLA2001

Valneva

Equities

VLA

FR0004056851

Biotechnology & Medical Research

Company Profile

Latest news about Valneva

Chart Valneva

Market Closed - Euronext Paris Other stock markets 11:38:10 2024-09-13 am EDT			5-day change	1st Jan Change
2.810 ^EUR	-10.45%		-8.77%	-40.47%

Sep. 13	A central bank and it's off again?
Sep. 13	Valneva: 15% discount for capital increase	CF

September 15, 2020 at 11:35 am EDT

Advancing Vaccines for Better Lives

VLA2001 - SARS-CoV-2 inactivated vaccine

15th September 2020

Valneva is a specialty vaccines company focusing on three unique programs

Inactivated SARS-CoV-2 vaccine

CONFIDENTIAL

15th September 2020

VLA2001 - SARS-CoV-2 inactivated adjuvanted vaccine

Inactivated vaccines have been successfully developed and marketed for decades

Selected inactivated vaccines

Japanese Encephalitis - IXIARO (Valneva)
Hepatitis A - Healive (Sinovac)
Flu - AFLURIA (Seqirus)
Polio - IPOL (Sanofi Pasteur)
Rabies - IMOVAX (Sanofi Pasteur)

New vaccine classes

No preventive RNA or DNA vaccines for human licensed

"Nanoparticles" - no licensed vaccine

Adenovirus envelope - unlicensed

Any one of these could revolutionise the vaccines field

Inactivated SARS-CoV-2 vaccine

CONFIDENTIAL

15th September 2020

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Original document
Permalink

Disclaimer

Valneva SE published this content on 15 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 September 2020 15:34:05 UTC

A central bank and it's off again?	Sep. 13
Valneva: 15% discount for capital increase	Sep. 13	CF
Valneva Raises EUR61 Million from Share Placement	Sep. 13	MT
Valneva Seeks EUR60 Million from Share Issuance	Sep. 13	MT
Pfizer: new positive data in Lyme	Sep. 03	CF
Pfizer, Valneva Report Positive Lyme Disease Vaccine Candidate Data	Sep. 03	DJ
Valneva, Pfizer's Second Lyme Disease Booster Shot Shows Antibody Response in Phase 2 Study	Sep. 03	MT
Valneva: new positive data in Lyme	Sep. 03	CF
Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate	Sep. 03	CI
Valneva: Groupe Grimaud La Corbière below 5% of share capital	Aug. 29	CF
Valneva: share price up, broker's analysis	Aug. 13	CF
Transcript : Valneva SE, H1 2024 Earnings Call, Aug 13, 2024	Aug. 13
VALNEVA : Oddo BHF confirms its recommendation on the stock	Aug. 13	CF
Valneva SE Reports Earnings Results for the Half Year Ended June 30, 2024	Aug. 13	CI
Valneva reports positive net income and rises on the stock market	Aug. 13	RE
Valneva: profits for the first half of the year	Aug. 13	CF
Valneva SE and LimmaTech Biologics AG Enter into Strategic Partnership and Exclusive Licensing Agreement for Development, Manufacturing and Commercialization of Shigella4V	Aug. 01	CI
Transcript : Valneva SE - Special Call	Aug. 01
Valneva: licensing agreement in shigellosis	Aug. 01	CF
Valneva Secures Exclusive License for Vaccine Candidate Against Shigellosis	Aug. 01	MT
Valneva: the Grimaud family falls below 10% of voting rights	Jul. 23	CF
Valneva Wins Additional $41 Million Grant for Chikungunya Vaccine Development	Jul. 22	MT
Valneva: partnership for Ixchiq extended with CEPI	Jul. 22	CF
Pfizer: primary vaccinations completed for VALOR trial	Jul. 18	CF
Valneva: primary vaccinations completed for VALOR trial	Jul. 18	CF

Duration

Period

More charts

Lyme disease

Chikungunya

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The group takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets two proprietary travel vaccines as well as certain third-party vaccines leveraging its established commercial infrastructure. Revenues from its growing commercial business help fuel the continued advancement of Valneva's vaccine pipeline. This includes the world's first vaccine against the chikungunya virus and the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.

Employees

700

Sector

Biotechnology & Medical Research

Calendar

2024-11-07 - Q3 2024 Earnings Release

More about the company